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Abstract Acute Coronary Syndromes (ACS) are a group
of disorders caused by the significant reduction of circu-
lation in coronary arteries. The most common reason of the
dysfunction is a blood clot formed in place of plaque
rupture. The role of scavenger receptors in development
and progression of atherosclerosis has been confirmed in
many animal experiments, however the knowledge about
contribution of the receptors in the development of ACS
symptoms in humans still remains insufficient. The aim of
this work was to define the expression of two scavenger
receptors: CD36 and MSR1 in monocytes of patients with
ACS after the onset of symptoms and after the 6 months of
treatment. The analysis of CD36 and MSR1 expression was
carried out with the use of real-time PCR and flow
cytometry. Analyses of lipid and glucose concentration in
blood and the level of inflammatory markers in plasma
were performed additionally for all ACS patients. All data
obtained during the research were analyzed using statistical
tests, such as Mann Whitney test, Wilcoxon test, or cor-
relation. In all patients with symptoms of ACS the amount
of CD36 and MSR1 mRNA in circulating monocytes, as
well as the density of both receptors on the cells surface
was significantly higher. Re-analysis of subjects after
6 months of treatment, showed a significant decrease in the
CD36 and MSR1 expression in all patients who received
atorvastatin. The results of presented studies demonstrate
that both investigated receptors are involved in the devel-
opment and/or progression of ACS.
Keywords Atorvastatin  Acute Coronary Syndromes 
Monocytes  CD36  MSR1
Abbreviations
HMG-CoA 3-Hydroxy-3-methylglutaryl-CoA
CD36 Macrophage scavenger receptor class B
MSR1 Macrophage scavenger receptor class A
LDL Low density lipoprotein
oxLDL Oxidized low density lipoprotein
ROS Reactive oxygen species
acLDL Acetylated low density lipoprotein
ACS Acute Coronary Syndromes
STEMI Acute myocardial infarction with ST
elevation




FSD Fluorescent surface density
CRP C-reactive protein
1 Introduction
Acute Coronary Syndromes (ACS) are a group of disorders
that can be caused by a significant reduction of blood flow
in coronary arteries due to narrowing or blockage of the
vessels. The most common reason of the vessel dysfunction
is the development of atherosclerotic lesions and a blood
clot formed in place of plaque rupture [2, 39]. Oxidised
lipoproteins (oxLDL) are the major factor responsible for
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the initiation and the acceleration of atherosclerosis. The
processes activated by oxLDL are: endothelial dysfunction,
expression of adhesion molecules, synthesis of chemoat-
tractants and proinflammatory cytokines, or activation of
monocytes and smooth muscle cells to migration into the
area of inflammation [4, 6, 10, 21]. Monocyte-derived
macrophages are able to bind and accumulate of modified
lipoproteins through the scavenger receptors-mediated
endocytosis [14–16, 34]. That is the main mechanism
responsible for the formation of atherosclerotic plaque,
because macrophages filled with cholesterol esters trans-
form into foam cells and form the lipid core of the plaque
[3, 29]. Scavenger receptors family is a large group of
proteins, divided into six classes (from A to F). All proteins
are able to recognize a large variety of ligands, such as:
oxidized or acetylated LDL lipoproteins, polyanions, or
apoptotic cells [11, 37]. The CD36, a type B scavenger
receptor, and the MSR1, a type A, are the main receptors
responsible for the uptake of modified lipproteins by
macrophages [12, 33, 42]. Both proteins are able to remove
70–90 % of modified LDLs, however CD36 is a receptor
responsible for oxLDL degradation, while the MSR1 is
mainly involved in the uptake of acetylated lipoproteins
(acLDL) [28].
The most common drugs used in the treatment of
hypercholesterolemia and the reduction of the risk of car-
dio-vascular events in patients with ischemic heart disease
are statins. The main therapeutic action of the drugs is the
lowering of endogenous cholesterol synthesis through the
inhibition of 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMG-CoA reductase)—the key enzyme of the
process [7, 27]. Recent studies on the lipid lowering drugs
showed also a wide range of pleiotropic activities of statins
that include enhancing of endothelial differentiation and
stabilization [5, 38], reduction of the expression of adhe-
sion molecule on the endothelial surface, suppression of
monocyte/macrophage activation and differentiation [9, 18],
inhibition of smooth muscle cell migration and proliferation,
or stabilisation of atherosclerotic plaque [19, 25, 36, 43]. A
very important object in the research on additional activities
of statins is the influence of the treatment on the uptake of
modified lipoproteins by macrophages. Statins are able to
reduce the level of LDL modifications due to their lipid-
lowering activity and through the reduction of reactive
oxygen species (ROS) concentration in plasma [1, 17, 23,
26]. However the influence of the drugs on the expression of
scavenger receptors, the process of oxLDL accumulation
and the foam cell formation remains unclear and is con-
stantly investigated [20, 30].
The aim of this work was to investigate the expression
of CD36 and MSR1 scavenger receptors in monocytes
isolated directly from fresh anticoagulated blood of
patients with ACS. The purpose of the first part was to
investigate alterations in the receptors expression in
patients after the onset of the ACS symptoms. In the second
part the experiments were repeated after the 6 months of
atorvastatin therapy to determine the effect of treatment on
the CD36 and MSR1 expression in monocytes.
2 Materials and Methods
2.1 Investigated and Control Group
Presented studies were carried out on the group of 100
patients with atherosclerosis, hospitalized for the onset of
symptoms of ACS, defined as acute myocardial infarction
with ST elevation (STEMI) or without (NSTEMI). The
whole group consisted of 32 females and 68 males, aged
from 33 to 78 years old (average 64). In 66 individuals
additional disorders were diagnosed also, such as diabetes
mellitus type 2 (NIDDM)—34 cases, arterial hypertension
(HTN)—56 cases, or obesity—14 cases. Before hospital-
ization none of the patients received statins and after the
onset of ACS symptoms in all analyzed cases the treatment
with statins was applied. The atorvastatin was received by
20 patients from the investigated group, in a dose of 40 mg
per day. 40 control subjects were also investigated, 20
females and 20 males, ranging from 26 to 54 years (aver-
age 37). The main criteria for selecting the control group
were normal laboratory findings, such as the lipid con-
centration in plasma, blood glucose level, C-reactive pro-
tein (CRP) level in plasma and good general health.
The material in the investigations presented was fresh
patient’s anticoagulated blood taken at the latest 24 h after
the onset of ACS symptoms, and after 6 months of therapy
with atorvastatin. The blood was used to extract DNA and
RNA, to implement the molecular analyses, such as real-
time PCR or flow cytometry, and to perform the basic
laboratory tests, such as blood lipid concentration, blood
glucose level or the level of C-reactive protein (CRP) in
plasma.
2.2 Monocyte Isolation
The first step of the analysis was to separate the monocytes
from other blood cells by density-gradient centrifugation in
Ficoll-Pague PLUS (GE Healthcare) and magnetic sepa-
ration with Dynabeads CD14 (Invitrogen). The isolation
was performed according to the manufacturers’ protocol.
Peripheral blood mononuclear cells obtained after ficoll
centrifugation were incubated with the superparamagnetic
polystyrene beads coated with monoclonal anti-CD14
antibodies and next the CD14? cells (monocytes) were
separated by placing the sample in a strong magnetic field.
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2.3 RNA Extraction and cDNA Synthesis
Purified monocytes were used directly to the total RNA
isolation using TRI REAGENT BD (Sigma Aldrich). The
procedure was performed according to the manufacturer’
procedure which was designed for RNA extraction from
blood cells, based on the single-step RNA isolation
reported by Chomczynski and Sacchi [8]. After the
extraction the concentration of RNA in samples was esti-
mated, by micro-volume UV-Vis spectroscopy (NanoDrop;
Thermo Scientific). The amount containing 500 ng of RNA
was used to reverse transcription PCR (RT-PCR) reaction.
The synthesis of complementary DNA (cDNA) was per-
formed in a total volume of 20 ll, using oligo(dT)18 primer
(100 ng/ll), RNase free, DEPC treated water and Revert-
AidTM M-MuLV Reverse Transcriptase (Fermentas).
2.4 Real-Time PCR Reaction
The real-time PCR reaction was used to determine the level
of CD36 and MSR1 transcripts in monocytes derived
from peripheral blood. The amplification was performed
with specific primers designed using oligo 6.65 software
(Rychlik and Rhoads 1989–2002). As a reference for the
analysis of CD36 and MSR1 expression was used gene
of porphobilinogen deaminase (PBGD). The real time
amplification (DyNAmoTM HS SYBR Green qPCR Kit,
Finnzymes) was carried out separately for the investigated,
CD36 and MSR1 genes and for the PBGD, in a final
reaction volume of 20 ll. The conditions of the reaction
were: hold at 95 C for 15 min, denaturation at 95 C for
10 s, annealing at 56 C for 15 s and elongation at 75 C
for 20 s, for 45 cycles. The final elongation was performed
at 72 C for 10 min and preceded by a process of the
appointing of melting curve, carried out at 72–95 C for
20 min. The specificity of the real-time PCR reaction was
based on the melting curve. All analyzes were performed
using the RotorGene 6000 software (Corbett Research).
2.5 Flow Cytometry Analysis
Flow cytometry was used to analyze the density of CD36
and MSR1 receptors on the surface of patient’s monocytes.
The process was carried out using 100 ll of anticoagulated
peripheral blood and monoclonal antibodies connected
with specific days. The antibodies targeted three different
antigens: CD36 (anti-Human CD36 FITC, Beckman
Coulter), MSR1 (anti-Human MSR1 PE, R&D Systems)
and CD14 (anti-Human CD14 PC5, Beckman Coulter).
The first two were used to determine the density of
investigated receptors, while the latter enabled the identi-
fication of monocyte population from all leukocytes. All
samples were incubated for half an hour with antibodies,
under conditions defined by manufacturers, and then pre-
pared for analysis through lysis of erythrocytes (formic
acid), leukocytes stabilization (PBS buffer) and parafor-
maldehyde fixation, using IMMUNOPREPTM Kit (Beck-
man Coulter). All analyses were performed using the Cell
Lab Quanta flow cytometer (Beckman Coulter).
2.6 Quantitative Determination of Oxidized LDL
in Plasma
For all patients the analysis of oxidized LDLs concentra-
tion in plasma with the use of enzyme immunoassay:
Oxidized LDL ELISA (Biomedica) was also performed. In
the assay polyclonal anti-oxLDL antibodies are absorbed
into microwells. Modified lipoproteins presented in sample
or in standard bound to the antibodies and then
HRPO(horseradish peroxidase)-conjugated monoclonal
anti-oxLDL antibody bound to modified LDL captured by
the first antibody. In the next step to the reaction, the
substrate for the enzyme was added and the amount of
colored product was measured. The colored product was
formed in proportion to the amount of oxLDL in investi-
gated plasma or standard and it was determined by the
measurement of absorbance at 450 nm, with the use of
microwell strip reader: Multimode Detection System DTX
880 (Beckman Coulter).
2.7 Statistical Analysis
For all data obtained during the research statistical analyses
were performed using GraphPad Prism 5 software. The
comparison of results for patients versus control group was
performed with the use of Mann Whitney test, while the
data obtained for patients before and after atorvastatin
treatment were analyzed with the use of Wilcoxon test. The
values of the oxLDL concentration in plasma were used to
define the correlation between the elevated concentration
of modified lipoproteins in plasma and the level of CD36
and MSR1 expression in monocytes of patients after the
onset of ACS symptoms. The value of p \ 0.05 was con-
sidered to be statistically significant.
3 Results
The results were divided into three parts. The first analysis
concerned the expression level of CD36 and MSR1 in
patients with ACS and the relations between the receptors
expression and oxLDLs concentration in plasma. The
second part was targeted on investigation of the alterations
in the CD36 and MSR1 genes expression after 6 months of
atorvastatin treatment. Additionally based on the values of
laboratory analysis the third part was established, which
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was the effectiveness of the therapy in the lipid and
inflammation lowering.
At the level of mRNA, the expression of investigated
genes was defined as a relative amount of CD36 and MSR1
transcripts normalized to a reference PBGD gene and rel-
ative to the healthy subjects, defined as 2-DDCT. At the
protein level the density of the scavenger receptors on the
monocte surface was determined by the level of specific
fluorescence emitted by stained antibodies connected with
investigated antigens, and defined as FSD (Fluorescent
Surface Density) parameter.
3.1 The Level of CD36 and MSR1 Expression
was Significantly Increased in All ACS Patients
The quantitative real-time PCR analysis of the CD36 gene
expression was performed for every patient and healthy
individual classified to the investigation. The expression
of CD36 was at least sixfold higher in all analyzed cases
of ACS in comparison to healthy control. The mean
amount of CD36 gene transcripts in monocytes was 6.88 ±
4.12 in the patients, while in the control group it was
0.94 ± 0.36 (Fig. 1). All results were statistically signifi-
cant (p \ 0.0001).
Analogously analysis were performed for the MSR1
gene. The level of MSR1 gene expression in monocytes of
patients after the onset of ACS symptoms was at least
fivefold higher than in healthy individuals. The mean
amount of MSR1 transcripts in the investigated group and
in control group was 5.87 ± 3.83 and 0.99 ± 0.5 respec-
tively (Fig. 2). All results were statistically significant
(p \ 0.0001).
Another step was the flow cytometric analysis. Based on
the FSD parameter value, both for the investigated and
control group was defined the density of the scavenger
receptors on the monocyte surface. For CD36 the FSD
parameter was determined on the basis of the level of
fluorescein isothiocyanate (FITC) fluorescence, while the
MSR1 FSD parameter was defined on the basis of the level
of Phycoerythrin (PE) fluorescence.
In all analyzed patients the density of both receptors on
the monocyte surface was significantly higher than in
healthy subjects. The mean values of CD36 FSD was
13.7 ± 7.35 and 2.47 ± 1.54 in the patients and in the
control group respectively (Fig. 3), while the FSD param-
eter for MSR was 7.12 ± 2.65 in the patients and 3.36 ±
0.8 in the control subjects (Fig. 4). All results were sta-
tistically significant (p \ 0.0001).
Fig. 1 The results of quantitative analysis of CD36 transcript level.
The graph on the left presents the mean value of relative expression of
CD36 gene in each analysed case (n = 3). On the right are presented
the relative amounts of CD36 transcript in the patients with ACS and
in the control group. Results are expressed as mean 2-DDCT
value ± SD. p \ 0.0001
Fig. 2 The results of quantitative analysis of MSR1 transcript level.
The graph on the left presents the mean value of relative expression of
MSR1 gene in each analysed case (n = 3). On the right are presented
the relative amounts of MSR1 transcript in the patients with ACS and
in the control group. Results are expressed as mean 2-DDCT
value ± SD. p \ 0.0001
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3.2 The Density of Both Receptors on the Surface
of Monocytes was Positively Correlated
with the Concentration of oxLDL in Plasma
Performed statistical analyses showed that there was no
statistically significant correlation between the concentra-
tion of oxLDLs and the level of CD36 or MSR1 transcripts.
However the analysis of data obtained from flow cyto-
metric measurements showed that there was a positive
correlation between the elevated concentration of oxidized
lipoproteins in plasma and increased density of both
investigated receptors on the monocyte surface (Fig. 5).
3.3 Atorvastatin Reduced the Expression of CD36
and MSR1 in All Patients
The second part of our investigation was the re-analysis
of the scavenger receptors expression in all patients,
after 6 months of atorvastatin treatment. Obtained results
showed a significant decrease in the expression of CD36
and MSR1 in all cases. The level of CD36 transcript
and MSR1 transcript was reduced down approximately to
levels observed in control group. The expression of CD36
was redused from 7.86 ± 4.43 to 1.37 ± 0.5, while the
expression of MSR1 was 6.45 ± 5.66 before the treatment
and 1.01 ± 0.42 after the atorvastatin therapy (Fig. 6).
Also the comparison of the flow cytometric results
showed the reduction of receptors density on the surface of
monocytes in all patients who received atorvastatin. The
density of CD36 after the onset of ACS symptoms was
16.84 ± 8.53 while after the treatment it was reduced to
the value of 2.77 ± 2.02. Similarly the density of MSR1
was decreased from 9.09 ± 3.24 to 2.39 ± 0.66 (Fig. 7).
All results were statistically significant (p \ 0.05).
3.4 The Values of Laboratory Tests Demonstrated
the Effectives of Atorvastatin Treatment
Analysis of blood lipid and glucose concentration and the
level of CRP in plasma were performed for all patients
after the onset of ACS symptoms and after the treatment.
The mean values of obtained data are presented in the table
below along with standard laboratory values for the per-
formed tests (Table 1.)
The six-month treatment resulted in significant (p \
0.05) reduction of total and LDL cholesterol concentration
in all patients who received atorvastatin. Similar results
were obtained for the blood glucose concentration and the
Fig. 3 The results of flow cytometric analysis of CD36 density on the
monocyte surface. The graph on the left presents the mean value of
FSD parameter in each analysed case (n = 3). On the right are
presented the mean values of CD36 density on monocyte surface in
the patients with ACS and in the control group, expressed as mean
value of FSD parameter ± SD. p \ 0.0001
Fig. 4 The results of flow cytometric analysis of MSR1 density on
the monocyte surface. The graph on the left presents the mean value
of FSD parameter in each analysed case (n = 3). On the right are
presented the mean values of MSR1 density on monocyte surface in
the patients with ACS and in the control group, expressed as mean
value of FSD parameter ± SD. p \ 0.0001
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level of inflammatory factors (CRP) in plasma, while
the HDL level and the serum triglycerides concentration
wasn’t significantly changed.
4 Discussion
The described research had the purpose of analyzing CD36
and MSR1 scavenger receptors expression in monocytes of
patients with ACS. The topic still remains important
because despite the fact that significant role of scavenger
receptors in the pathogenesis of atherosclerosis has been
confirmed in many experiments [12, 14–16, 28, 33, 42],
carried out mostly in animal models, the knowledge about
contribution of the receptors in the development of ACS
symptoms in humans still remains insufficient.
Data obtained in our investigations demonstrate that in
patients with ACS the expression of CD36 and MSR1 is
Fig. 5 Correlation between the
concentration of oxLDL in
plasma and the density of
investigated receptors on the
surface of monocytes. The
graph on the left shows the
results for CD36 (r = 0.35;
p = 0.0017), while the graph on
the right presents the correlation
for MSR1 (r = 0.26; p = 0.02)
Fig. 6 The effects of
atorvastatin treatment on the
CD36 and MSR1 expression.
Results are expressed as mean
2-DDCT value ± SD. The
p value is respectively:
p \ 0.0001 and p = 0.0017
Fig. 7 The effects of
atorvastatin treatment on the
density of CD36 and MSR1 on
the monocyte surface. Results
are expressed as Mean FSD
parameter value ± SD. The
p value is respectively:
p \ 0.0001 and p = 0.002
Table 1 The values of laboratory blood tests for patients with ACS,


















1.34 ± 0.4 1.4 ± 0.36 1.68–2.5
Triglicerydes
(mmol/l)
1.59 ± 0.84 1.33 ± 0.5 0.6–1.7
Glucose
(mmol/l)
8.06 ± 3.15 5.65 ± 0.8 3.9–6.1
CRP (mg/dl) 74.15 ± 31.53 1.97 ± 1.88 B3
The data is presented as the mean values along with standard values
for the performed tests
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significantly increased already in the circulating mono-
cytes. This fact is in contradiction with some of the pre-
vious hypotheses that the expression of scavenger receptors
is significantly increased especially during the evolution of
monocytes to macrophages [20]. In patients with ACS up-
regulated expression of investigated receptors in circulat-
ing monocytes can be strongly associated with the late
stage of atherosclerosis, because the onset of acute symp-
toms is characterized by increased activity of monocytes
and macrophages, as well as very high level of inflam-
mation in the organism [4, 21, 39]. This hypothesis was
confirmed in presented research through the analysis of the
C-reactive protein concentration in plasma, which showed
that in patients with acute coronary syndrome the level of
CRP was even 100 fold higher than the accepted standards
for healthy people. Another step in our investigation about
the role of scavenger receptors in the development and
progression of atherosclerosis was the analysis of correla-
tion between the level of oxidized lipoproteins in plasma
and the expression of investigated receptors on the surface
of monocytes. For all patients with ACS, measurements of
oxLDL concentration was performed and obtained data
were compared with the results of CD36 and MSR1
expression in monocytes. For both receptors the statistical
analyses showed positive correlation between the den-
sity of receptors on monocyte surface and the elevated
concentration of modified lipoproteins in plasma. These
findings seem to confirm the relationship between the
elevated level of CD36 and MSR1 expression and the
cardio-vascular disorders, however low correlation coeffi-
cient in both cases (rCD36 = 0.35 and rMSR1 = 0.25) and
lack of correlation between the level of CD36/MSR1
mRNA and the oxLDL concentration suggest that this topic
requires further investigation. Some findings also suggest
that the level of MSR1 gene expression increases only
during the monocyte to macrophages differentiation
[22, 31], however the results of our study showed that it
may be increased already in circulating monocytes, par-
ticularly in patients after acute myocardial infarction. For
this reason our findings suggest that the analysis of scav-
enger receptors can be useful in the diagnostics of the
cardio-vascular risk in patients, however this issue need
further investigations.
In the second part of the study, our goal was to dem-
onstrate the effect of atorvastatin therapy on the level of
CD36 and MSR1 expression. The effectiveness of the
treatment was confirmed through the laboratory tests,
because in all patients who received atorvastatin the values
of LDL, glucose and CRP concentration in blood returned
to the level suitable for healthy individuals. Moreover,
performed analyses showed that the treatment didn’t sig-
nificantly influence the level of blood HDL level, and these
results are characteristic for the atorvastatin activity [25].
The influence of statins on the monocytes/macrophages
activation, oxLDL accumulation and formation of foam
cells still remains valid, because the results obtained so far
come mainly from studies carried out in the in vitro con-
ditions, and available data is often contradictory and
ambiguous. For example the treatment with pravastatin
didn’t show effects on the uptake of modified lipoproteins
by macrophages derived from hipercholesterolemic sub-
jects [27]. It is noteworthy also that in rats with metabolic
disorders the cerivastatin therapy led to increased expres-
sion of CD36 receptors [32]. Oppositely, the findings
obtained from in vitro studies on the effects of fluvastatin,
simvastatin or lovastatin therapy on the level of scavenger
receptors expression demonstrated that the drugs signifi-
cantly decreased the expression of LOX-1, SRA-I, SRA-II
and CD36 [13, 24, 35, 40, 41]. In our investigations, the
atorvastatin therapy had an impact on the level of CD36
and MSR1 expression in circulating monocytes. In all
patients the level of CD36 and MSR1 mRNAs, and the
density of the receptors on the surface of monocytes was
reduced down from three to sixfold, to levels observed in
the control group. The results confirmed findings obtained
for in vivo investigations of monocytes of patients with
Type 2 Diabetes [30] and are in agreement with similar
investigations carried out on monocyte-derived macro-
phages of patients with hypercholesterolemia [20]. Obtained
results suggest that atorvastatin reduces the expression of
investigated receptors, however the treatment also had an
influence on other factors that may be associated with the
expression of CD36 and MSR1, thus, a direct mechanism of
atorvastatin action requires further research.
5 Conclusion
The results of presented studies demonstrate that in patients
with the onset of symptoms of ACS highly up-regulated
expression of CD36 and MSR1 in the circulating mono-
cytes is connected with the progression of the coronary
disease, and confirm the role of scavenger receptors in the
development of cardio-vascular disorders. The findings
also suggest that atorvastatin significantly reduces the
expression of scavenger receptors, however due to the wide
range of pleiotropic effects of statins the direct mechanism
of the drug activity remains unclear.
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